Analysts Offer Insights on Healthcare Companies: Veracyte (NASDAQ: VCYT) and Acer Therapeutics (NASDAQ: ACER)

By Jason Carr

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Veracyte (VCYTResearch Report) and Acer Therapeutics (ACERResearch Report).

Veracyte (VCYT)

In a report issued on November 14, Stephen Unger from Needham maintained a Buy rating on Veracyte, with a price target of $34.00. The company’s shares closed last Monday at $25.24.

According to TipRanks.com, Unger is a 4-star analyst with an average return of 13.7% and a 74.3% success rate. Unger covers the Healthcare sector, focusing on stocks such as Myriad Genetics, Thermo Fisher, and PerkinElmer.

Currently, the analyst consensus on Veracyte is a Moderate Buy with an average price target of $34.00.

See today’s analyst top recommended stocks >>

Acer Therapeutics (ACER)

In a report issued on November 14, Serge Belanger from Needham reiterated a Hold rating on Acer Therapeutics. The company’s shares closed last Monday at $3.33, close to its 52-week low of $1.87.

According to TipRanks.com, Belanger is a 1-star analyst with an average return of -1.3% and a 40.5% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Collegium Pharmaceutical, and KalVista Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Acer Therapeutics with a $10.00 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.